NASDAQ
NMTC
Last Price
US $2.43
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
NeuroOne Medical Technologies Corporation cash flow to debt ratio of -1.06K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
NeuroOne Medical Technologies Corporation's free cash flow has increased -73.78% from $-11.13M last year to $-2.92M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
NeuroOne Medical Technologies Corporation's debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
NeuroOne Medical Technologies Corporation's debt has decreased relative to shareholder equity from 0.32 last year to 0.04 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
NeuroOne Medical Technologies Corporation has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
NeuroOne Medical Technologies Corporation's interest coverage ratio of 21.76 indicates that earnings with good margin can cover interest payments on company debt
Financial stability - Profit margin growth.
NeuroOne Medical Technologies Corporation's profit margin has increased (-80.84%) in the last year from -356.74% to -68.34%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
NeuroOne Medical Technologies Corporation's short-term assets of $10.23M exceed its short-term liabilities of $2.30M
Decreasing performance - ROA.
NeuroOne Medical Technologies Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
NeuroOne Medical Technologies Corporation's return on equity of -98.33%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
NeuroOne Medical Technologies Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
NeuroOne Medical Technologies Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
NeuroOne Medical Technologies Corporation has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
NeuroOne Medical Technologies Corporation has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
NeuroOne Medical Technologies Corporation's yearly earnings has increased -70.73% since last year from $-12.32M to $-3.61M, signaling increasing performance
Increasing performance - Healthy revenue growth.
NeuroOne Medical Technologies Corporation's yearly revenue has increased 250.35% since last year from $3.45M to $12.10M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -112.33% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
NeuroOne Medical Technologies Corporation's 3-year revenue CAGR of 313.45% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
NeuroOne Medical Technologies Corporation had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
NeuroOne Medical Technologies Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
NeuroOne Medical Technologies Corporation has insufficient data to evaluate this check.
Overvalued - Earnings yield.
NeuroOne Medical Technologies Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
NeuroOne Medical Technologies Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
NeuroOne Medical Technologies Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
NeuroOne Medical Technologies Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
NeuroOne Medical Technologies Corporation has a price-to-book ratio of 3.81x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
NeuroOne Medical Technologies Corporation has a price-to-sales ratio of 2.11x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-98.33%
Return on equity
ROIC: -112.33%
Valuation History
-3.3X
Price to Earnings
EV/EBITDA: -3.5X
Cash flow
Profit margin
10.03%
(FY vs FY)
Cash flow Y/Y
3.98%
(FY vs FY)
Fair Value
Market $2.43
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.